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MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression.
To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied
models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the
Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this
comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined
tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most
frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally,
tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active
oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate
continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are
important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the
miRNA target spectrum responds to staged tumorigenesis.
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Prostate cancer (PCa) is the most commonly diagnosed noncutaneous
cancer and the second leading cause of cancer-related death in men in
the United States [1]. The disease is primarily driven at all stages by
activation of the androgen receptor (AR) [2,3]. Various strategies
designed to limit AR activity are the current standard of care for
recurrent and metastatic PCa. Although androgen deprivation
therapy often results in a substantial clinical response, the disease
invariably recurs in a lethal, castrate-resistant manner in which AR is
frequently reactivated in the absence of androgens [2,3]. During
intense antiandrogen therapy, a small percentage of men develop
treatment-emergent AR-negative small cell/neuroendocrine PCa, a
highly aggressive, androgen-independent tumor [4]. Various pub-
lished studies have cataloged somatic point mutation, copy number
aberration, and epigenetic and transcriptomic pathway alterations
that occur during the clinical progression of PCa in tumors and model
cell lines [5–12]. Together, these analyses have defined the molecular
alterations associated with PCa progression.
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RNA molecules that exert posttranscriptional control over gene
expression at the level of mRNA through translational inhibition and
initiation of mRNA degradation [13]. In cancer, miRNAs have been
shown to have broad oncogenic and tumor-suppressive roles across
many tumor types [14], implicating them as key regulators of cancer
biology. miRNA expression is broadly deregulated in PCa, and
considerable evidence suggests that miRNAs play a role in PCa
progression [15–21]. However, to date, the global changes in the
miRNA target spectrum (targetome) present at various stages of PCa
progression have yet to be comprehensively defined.
To define the global miRNA targetome in PCa, we performed
photoactivatable ribonucleoside-enhanced cross-linking immunopre-
cipitation of the Argonaute protein (AGO-PAR-CLIP) [22,23] to
broadly map interactions between miRNAs and their cognate miRNA
target sites across cell line models of PCa progression. We included
the androgen-responsive, AR-positive models LNCaP and LAPC4
and the castrate-resistant PCa (CRPC) model 22Rv1 [3,24,25]. To
model treatment-emergent small cell/neuroendocrine PCa, we also
included the AR-negative lines DU145 and PC3.
We found that miRNAs persistently target primary drivers of PCa
even in advanced tumor models. We noted an example of
stage-specific driver targeting by miR-148a,which acts as an
oncomiRNA in early PCa models by targeting CDKN1B but also
acts as a metastatic suppressor by targeting CENPF. Globally,
miRNAs reactively target the E2F and MYC pathways active in
CRPC as well as the epithelial-to-mesenchymal transition (EMT) and
glycolytic pathways active in AR-negative PCa. More broadly, we also
found that miRNAs target components of the oxidative phosphor-
ylation machinery that is known to be uniquely active in PCa [26].
Treatment of castrate-sensitive LNCaP cells with the AR antagonist
MDV3100 (enzalutamide) led to global depletion of miRNA binding
to the 3’UTR that corresponds with the well-known cytostatic
properties of full AR blockade, suggesting plasticity in miRNA
targeting of oncogenic pathways. Finally, we found that the target
pathways we identified are associated with multiple clinical end
points, including recurrence. In sum, miRNAs globally undergo a
homeostatic response to driver pathways activated during stage-
specific PCa progression. AGO-PAR-CLIP offers a novel approach to
identify new stage-specific drivers of PCa.
Material and Methods
Cell Culture and Cell Line Acquisition
All cell lines in this study were obtained directly from the Baylor
College of Medicine Tissue Culture Core. All cells had been regularly
screened for infection and had undergone DNA fingerprint
verification to determine authenticity. PC3, DU145, LAPC4,
LNCaP, and 22Rv1 PCa cells were maintained in DMEM:F12,
EMEM, IMDM, and RPMI 1640 (Invitrogen, Carlsbad, CA) cell
growth medium, respectively. All growth media were supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT). Cells were
cultured in a humidified atmosphere at 37°C and in 5% CO2.
AGO-PAR-CLIP Dataset Production
AGO-PAR-CLIP was performed as a modified protocol similar to
one previously described [27] using the Millipore 11A9 anti-AGO2
antibody, with one major modification: the Illumina TruSeq kit was
used for indexed cDNA library synthesis. Samples were thenmultiplexed with up to eight samples per lane on an Illumina
HiSeq 2000 machine (Supplementary Files 1–2, Supplementary
Figure 1, A–C). To define cluster sites, we processed AGO-PAR-
CLIP data through PARalyzer [28] and Piranha [29], and clusters
were then mapped onto the GC19 transcriptome (Supplementary
Figure 1D). We compared unique reads in our datasets with those
reported in AGO-CLIP data and found similar percentages of unique
reads (Supplementary Figure 1E). Additionally, we found enrichment
in the T→C transitions (and complementary C→G transitions)
expected in AGO-PAR-CLIP datasets (Supplementary Figure 1F).
Availability of Supporting Data
The raw reads of each data set supporting the results are available in the
National Institutes of Health sequence read archive under the bioproject
accession SRP075075, PRJNA321524. Processed AGO-CLIP data atlas
files are uploaded in Synapse to the stable hyperlink Synapse ID
syn5479902 (https://www.synapse.org/#!Synapse:syn5479902).
CLIP Dataset Mapping and Computational Analysis
CLIP datasets were processed through two of three pipelines.
AGO-PAR-CLIP datasets were processed through Bowtie 1 [30] and
Bowtie 2 [31], and clusters were called using the PARalyzer
algorithm [28] for Bowtie 1 mapped reads and the Piranha
algorithm [29] for Bowtie 2 mapped reads. AGO-HITS-CLIP
datasets were processed through Bowtie 2 or Novoalign, and clusters
were called using the Piranha algorithm for Bowtie 2 mapped reads
and the CIMS [32] algorithm for Novoalign mapped reads. Unique
reads were filtered using Samtools [33].
Clusters were then mapped onto the Gencode 19 transcriptome and
processed through the TargetScan miRNA-seed motif-calling algo-
rithm [34] and assembled into an atlas of miRNA target files in a manner
similar to that previously described. Our CLIP atlas was updated to
include new human and mouse CLIP data [14,22,23,35–50]. For the
CLIP atlas, PARalyzer clusters were used for AGO-PAR-CLIP data and
Piranha clusters were used for AGO-HITS-CLIP data. CLIP binding
data were visualized in Circos [51]. Read coverage in clusters was
determined using Bedtools [52]. All read files used to determine cluster
coverage were processed through the same mapping pipeline (Bowtie 2).
Unique reads were used for cluster coverage, and complete read files were
used for miRNA coverage.
Once assembled, coverage files were filtered for N1 read in N50%
of analyzed datasets and then upper-quartile normalized in EdgeR
[53] as counts per million in the genome segment of interest (e.g.,
miRNA, 3’UTR, all clusters). Gene set enrichment analysis (GSEA)
[54] was used for read counts summed per gene to determine pathway
enrichment. The Kyoto Encyclopedia of Genes and Genomes
(KEGG) [55] and Panther [56] were used to perform analysis of
binary peak calls. The AGO-CLIP atlas was mined for cluster data
using custom scripts.
Clinical Correlation Analysis
Starting with the core-enriched gene signatures as defined by
GSEA differential AGO-CLIP binding analysis, we evaluated the
activity of each gene signature on a per-sample basis in the Taylor
dataset [5]. To determine the activity score for each core-enriched
gene signature, we first computed the z-score for the gene signature
expression within the cohort, as previously described [5], and then
computed the sum z-score for each patient. The z-scores of genes with
low AGO-CLIP binding were subtracted from the z-scores of genes
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score for each specimen.
The association of the gene signatures with biochemical recurrence
(BCR)–free survival was evaluated in a large PCa patient cohort for
which gene expression profiles and clinical outcomes have been
reported [5]. Gene signature activity for each patient was computed as
described above. Within the patient cohort, specimens were ranked
according to their gene signature activity score into quartiles (top
25% and bottom 75%, top 50% and bottom 50%, top 75% and
bottom 25%), and association with BCR-free survival was evaluated
using the log-rank test. The package “Survival” in the R statistical
system was used to assess significance. Similar survival analysis was
performed for CENPF using only CENPF gene expression data.
Following BCR-free survival analysis for all gene sets, we focused
on the E2F and G2M gene sets for subsequent clinical associations,
including Gleason score, ERG fusion status, tumor stage, patient race,
extra-capsular extension, probability of lymph node metastasis,
probability of seminal vesicle invasion, probability of organ-confined
disease, prostate-specific antigen levels at diagnosis, and development
of clinical metastasis. Of all analyzed associations, only the Gleason
score was significantly correlated with the gene signatures. Gleason
score groups were defined as follows: high N 7, intermediate = 7, low
b 7. Significant associations were identified using an unpaired
two-sided t test (Pb .05 was considered statistically significant).
Proliferation Assays
Proliferation data were obtained in LNCaP cells transfected with
miR-148a mimic and control mimic (Invitrogen), with Lipofectamine
2000 (Invitrogen) as the transfection reagent, using an Edu click-it flow
cytometry assay kit and TOPRO-3 as a total DNA counterstain
(Invitrogen). LNCaP proliferation experiments were performed in
triplicate measurements of 50 nM and 100 nM. Proliferation was
measured after 48 hours; concentrations yielded similar results and were
pooled for final analysis (n= 6 per group). Samples were analyzed by flow
cytometry (FACSCanto II, BD Biosciences, San Jose, CA), with a
minimum of 20,000 events. Data were analyzed using FlowJo software
(Tree Star Inc., Ashland, OR). Statistical differences between treatment
groups were evaluated using the Student t test.
Luciferase Assays
CDKN1B luciferase assays were performed in 293T cells,
transfected once with 5 nM, once with 10 nM, and twice with
50 nM of miR-148a using Lipofectamine 2000 (6 replicates per
group with pooled analysis, n= 24 per group). The CDKN1B plasmid
was obtained from Addgene (Plasmid 21326: pGL3-Control-PTE-
N-3'UTR-Wt [29] and Plasmid 20881: pGL-p27UTR) [32]. Assays
were performed twice using 50 nM of miR-148a mimic or control
mimic (n= 6 and n= 4 per group). The CENPF 3’UTR luciferase
construct was obtained from Switchgear Genomics (Carlsbad, CA) and
performed in 293T cells using the Lightswitch assay kit according to
manufacturer protocols. CENPF 3’UTR luciferase assays were
performed twice at 20 nM and 50 nM (n= 4 and n= 7; one sample
was excluded because of incomplete mixing) and twice at 50 nM (n= 4
and n= 4). Replicates were grouped for statistical analysis (n= 19 per
group). Assays were performed twice in quadruplicate using 50 nM
miR-148a mimic or control mimic. Comparisons were made using an
unpaired two-sided Student’s t test. β-Galactosidase transfection
controls were not used in the CENPF assay per the protocol defined
by Addgene/Switchgear genomics for its vectors.Site-directed mutagenesis was performed using a QuikChange II
XL site-directed mutagenesis kit (Agilent Biosciences, Santa Clara,
CA) with primer sequences:
CENPF:
Fwd: TGAAAAAGTTTGGAAGCATGAATCACCTGTTA
GCATT
Rev: AATGCTAACAGGTGATTCATGCTTCCAAA
CTTTTTCA
CDKN1B:
Fwd:GGACATCCTGTATAAGCTGAGAGAAAGCAAAAA
CAAT
Rev: ATTGTTTTTGCTTTCTCTCAGCTTATACAGGA
TGTCC
Western Blotting
Primary antibodies included CENPF (DM1A; Santa Cruz
Biotechnology, Santa Cruz, CA), AR (ab5; Abcam Inc., Boston,
MA), CDKN1B/p27 Kip1 (D69C12) XP Rabbit mAb 3686 (Cell
Signaling, Danvers, MS), and AGO2 (11A9, Millipore, Darmstadt,
Germany). miR-148a Western blot analysis was performed twice in
biological triplicate using transfection with 50nM miR-148a.
Quantitative polymerase chain reaction (PCR)
RNA was extracted from cells using the RNeasy Mini kit (Qiagen,
Germantown, MD) or the miRvana total RNA extraction kit
(Invitrogen). RNA was reverse-transcribed into cDNA using
SuperScript III First-Strand Synthesis SuperMix (Invitrogen), and
the cDNA was quantified using real-time PCR (StepOne PLUS
Real-Time PCR System; Applied Biosystems, Foster City, CA) with
the CENPF TaqMan Gene Expression Assays (Hs01118845_m1;
Applied Biosystems) or has-miR-148a Taqman assay relative to U6
snoRNA Taqman assay (Invitrogen). Gene expression was normal-
ized to GAPDH TaqMan Gene Expression Assays (Hs02758991_g1;
Applied Biosystems) using the ΔΔCT method. Statistical differences
between treatment groups were evaluated using the Student’s t test.
Migration Assay
Cell migration was determined by the wound-healing assay in PC3
cells. Transfected cells were incubated for 3 days to reach confluence,
then streaked with a sterile pipette tip and allowed to recover for 24
additional hours. Five random fields per sample were visualized and
photographed with a microscope at 4× magnification immediately
and 24 hours after wounding. Transfection of CENPF siRNA was
performed twice in biological triplicate; replicates were combined for
statistical analysis (n= 6 per group). Statistical differences between
treatment groups were evaluated using a two-sided Student’s t test.
Invasion Assay
Invasion assays were performed using BD BioCoat Matrigel
Invasion Chambers in PC3 cells (BD Biosciences). Three days after
transfection, 1.5 × 105 cells were replated onto each Matrigel-coated
insert. RPMI medium supplemented with 5% fetal bovine serum
(Hyclone) was added to the lower chamber to act as a chemoat-
tractant. Cells were allowed to invade through the Matrigel and 8-μm
pore membrane for 24 hours. Noninvasive cells and matrix were
removed using a cotton swab. Membranes were fixed in 4%
paraformaldehyde, stained with 0.5% crystal violet, and air-dried,
and six random fields per sample were then visualized and
Figure 1. Workflow of the AGO-PAR- CLIPdata analysis. After transcriptome mapping, clusters were processed through three different
algorithms (Panther, EdgeR, and GSEA) to determine altered miRNA target sites and pathways enriched in miRNA targeting between
groups. The Panther database was used to analyze binary cluster calls in the form of gene lists. Target sites were analyzed in EdgeR to
normalize read data at each target site and define target sites that underwent rigorous statistical change. Similarly, GSEA was used to
analyze normalized read data at individual target sites (summed per gene) to identify statistical enrichment of pathways in which miRNA
targeting was activated between cell types or treatments. Finally, once pathways enriched for miRNA targeting were discovered, the
genes involved in those pathways were analyzed to identify associations with clinical end points in large publically available cancer
datasets.
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cells were transfected with miR-148a at 50 nM and 100 nM in
triplicate; groups were combined for statistical analysis (n= 6 per
group). Transfection of CENPF siRNA was performed twice in
biological triplicate; replicates were combined for statistical analysis
(n= 6 per group). Statistical differences between treatments were
evaluated using an unpaired two-sided Student’s t test.
Results
AGO-PAR-CLIP miRNA Target Definition in PCa Cells
To experimentally characterize the miRNA targetome, we performed
AGO-PAR-CLIP coupled with deep sequencing on the LNCaP, 22Rv1,
LAPC4, DU145, and PC3 cell lines as described previously, with several
modifications (see Methods, Supplementary Files 1–2). To identify
differences in miRNA targetomes among the cell lines, we performed
gene ontology analysis using transcripts that exhibit differential miRNA
activity at individual clusters. We employed three independent
approaches to characterize miRNA target activity: statistical overrepre-
sentation of binary cluster gene lists (Panther and KEGG), statistically
different read depths at miRNA target sites (EdgeR), and read depth
enrichment in miRNA target sites of gene sets (GSEA; Figure 1).
We found that our prostate AGO-PAR-CLIP datasets demon-
strated similar levels of 3’UTR and coding sequence cluster
enrichment, defined as clusters per gigabase, as those observed in
an atlas containing published AGO-PAR-CLIP datasets (Figure 2A,
Supplementary File 3) [14]. Our data also contained similar numberof unique reads, T→C transitions, and clusters as previously
published data (Supplementary File 3). Small RNA loading onto
AGO can be determined from AGO-CLIP data, providing a
description of which miRNAs are active in the cell. Highly expressed
miRNA families, as defined by miRNA loading onto AGO
(Supplementary File 4), had 50% (P= 1.7e-9) more identified target
sites than all other families (Figure 2B), demonstrating that target
discovery in CLIP data is proportionate to miRNA expression.
AGO-CLIP sequencing (AGO-CLIP-Seq) data experimentally
defined miRNA targets at all genomic locations, including the
3’UTR, 5’UTR, coding sequence, noncoding RNA, intron,
promoter, and intergenic regions (Figure 2A). We found targeting
in all of these regions, supporting the results of recent studies showing
noncanonical AGO binding [46,57,58]. In the current analysis, we
restricted our focus to canonical 3’UTR interactions to define
miRNA target pairs that are likely to mediate mRNA regulation [59].
We focused on seed-compliments of conserved miRNA families
defined by TargetScan [34,60] because expression of conserved
miRNAs is more detectable across tissues and less likely to represent a
false positive [14]. Hierarchical clustering of read depth at 3’UTR
target sites using this approach in PCa cell lines demonstrated that
replicates from the same cell lines cluster together and those from
AR-positive cell lines cluster separately from those from AR-
negative cell lines (Figure 2C). This finding indicates that miRNA
targeting of mRNA 3’UTRs is consistent across replicates and is
tissue specific, with similar cell lines exhibiting similar miRNA
targetomes.
Figure 2. AGO-PAR-CLIP-Seq defines the miRNA target spectrum (targetome) in PCa cell lines. (A) PCa CLIP datasets were enriched for
PARalyzer clusters in the 3’UTR. CDS indicates coding sequence; ncRNA, noncoding RNA. Error bars are standard error of the mean. (B)
Fractional enrichment of target sites in PCa CLIP datasets for miRNA families with the highest expression (top most expressed miRNA
families) demonstrated the specificity of CLIP data based on the ability of the data to proportionately capture interactions of the most
highly expressed miRNAs. (C) Hierarchical clustering of miRNA targets in PCa showed that the targetome in AR-positive cell lines was
separate from that of AR-negative PCa cell lines.
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Because PCa undergoes discrete and stage-specific molecular
alterations during progression, we first sought to define which
miRNAs target known drivers of PCa. We curated a list of 22
previously described PCa drivers (Figure 3A) [3,5–7,10–12,61–66]
and then analyzed the total amount and composition of miRNA
binding on the 3’UTR of each driver mRNA (Figure 3A).
Most miRNA families targeted each PCa driver only once along its
3’UTR (Figure 3A). However, miR-185 and miR-9 each had greater
than three target sites on the AR 3’UTR, suggesting that these
miRNAs may strongly regulate AR (Figure 3A). miR-146 had four
target sites on APC, and miR-204 had four target sites on NCOA2.Figure 3. MicroRNA-mediated targeting of drivers of PCa. (A) Interse
driver gene are shown. PCa tumor suppressors are represented in blu
unique driver targets per miRNA is represented in blue (most unique
miR-148a family had the most unique driver targets in PCa. White c
color-coded to indicate the total number of miRNA target sites per
indicates five (the highest number of recurrent target sites per miRN
involved only a single target site per 3’UTR. However, the miR-185 m
family targeted AR at five different sites along the 3’UTR. (B) miRNAs c
AR was the PCa driver most heavily bound by miRNAs. (C) PCa drive
drivers and genes with at least one CLIP target site are represented i
mean. (D) AR binding across AR-positive cell lines was variable; most
AR-negative cell lines.The remaining miRNAs targeted each driver at less than four points
along their 3’UTRs (Figure 3A). The miR-148a miRNA family
targeted the most PCa drivers (nine unique targets), followed by the
miR-203, miR-28, and miR-539 families, which each targeted eight
unique PCa drivers (Figure 3A).
In total, 129 of 148 conserved miRNA families (87%) targeted at
least one PCa driver, indicating convergent miRNA targeting even on
a small number of genes. All PCa driver genes except FOXM1 had at
least one miRNA target site identified in the PCa CLIP data
(Figure 3B). Differential levels of miRNA targeting between PCa
driver genes defined which driver pathways were most susceptible to
miRNA regulation. Among tumor suppressors, APC, PTEN, andctions of PCa drivers and all miRNA families that target N1 unique
e, and PCa oncogenes are represented in red. The total number of
targets) and orange (least unique targets) in the second line. The
ells indicate no targeting was present, and the remaining cells are
target per miRNA family; red indicates one target site and blue
A identified in this analysis). Most miRNA targeting on PCa drivers
iRNA family targeted the AR at four different sites, and the miR-9
ontributed to the regulation of almost all PCa drivers in our analysis.
rs were enriched for miRNA binding relative to all other genes. All
n the graph. **Pb .0005 (t test). Error bars are standard error of the
binding occurred in the 22RV1 line. No AR binding was detected in
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In the case of PTEN, our results are consistent with published data
demonstrating that noncoding RNAs, including miRNAs, contribute
to tumor progression by targeting PTEN [67,68].
Overall, the PCa driver genes also had, on average, twice as many
miRNA seed sites and twice as many CLIP clusters per 3’UTR as all
other genes with at least one identified cluster (Figure 3C). This
finding suggests preferential targeting of the miRNA pool to
dominant oncogenic gene programs. AR had the most 3’UTR
miRNA seed sites (147 total seed sites representing 71 unique
miRNA families, Figure 3B), as well as the most 3’UTR clusters (73
total clusters, Supplementary Figure 2A), indicating that the AR
transcript is under potent regulatory control by many different
miRNAs. Consistent with these data, AR ranked in the top 5% of
targeted genes across the AR-positive AGO-CLIP datasets, corrob-
orating previous studies indicating that multiple miRNAs are capable
of regulating AR expression, including the miR-135, miR-185,
miR-34, miR-421, and miR-9 families [69]. We also observed the
strongest AR targeting in 22RV1, suggesting differential targeting
across the AR-positive cell lines (Figure 3D).
miR-148a Targeting of CDKN1B and CENPF
Because the miR-148ab family had the most PCa driver targets and
is the highest expressed miRNA in PCa cell lines (Supplementary
File 4), we selected miR-148a to validate our CLIP-based PCa driver
analysis. The function of miR-148a in PCa remains controversial.
Previous studies of PCa cell lines showed that miR-148a was weakly
androgen responsive [17,19] and exogenous miR-148a expression
enhanced AR-positive LNCaP growth [19]. However, in the
AR-negative PC3 cell line, miR-148a was shown to prevent
proliferation, migration, invasion, changes in cellular polarity, and
chemotherapy resistance [21]. Although there is no current consensus
on the net tumorigenic or tumor-suppressive potential of miR-148a
in PCa, the available data suggest that miR-148a activity in PCa may
be context specific [15].
Clinical PCa data [5] indicate that miR-148a expression increases
in primary tumors but is progressively silenced in metastatic disease
(Figure 4A). In the PCa cell lines LNCaP and PC3, miR-148a
mimicked its differential expression in prostate tumors: miR-148a
expression relative to normal prostate cells was increased in LNCaP
and decreased in PC3 cells (Supplementary Figure 2B). These
expression differences in LNCaP and PC3 cells are consistent with the
significant loss of miR-148a CLIP binding sites that we observed in
PC3 and DU145 cells relative to LNCaP and LAPC4 cells
(Figure 4B). Treatment of PC3 cells with miR-148a mimic was
sufficient to rescue miR-148a CLIP targeting, demonstrating the
specificity of these interactions (Figure 4B). In validation experi-
ments, we confirmed that miR-148a is capable of increasing
proliferation in LNCaP cells by enhancing the S-phase transition
(Figure 4C, Supplementary Figure 2C). We also confirmed that
miR-148a significantly reduced PC3 cellular migration, suggesting
that miR-148a has potent antimetastatic properties (Figure 4D).
These findings are consistent with a model wherein miR-148a
contributes to early PCa tumorigenesis but hinders metastatic disease.
In our PCa driver target analysis, miR-148a targeted AR, KMT2A,
FOXA1, MYC, CENPF, and PIK3CA oncogenes and APC, PTEN,
and CDKN1B tumor suppressors. We hypothesized that targeting of
both tumor-suppressive and oncogenic drivers of PCa may contribute
to the contextual role of miR-148a. To determine which PCa driversare most likely to be strongly regulated by miR-148a, we performed
orthogonal computational analysis of miR-148a targeting using
miR-148a overexpression arrays in LNCaP cells and miR-148b
overexpression arrays in HeLa cells [17,70], as well as correlative
analysis of PCa tumors [5]. Specific examination of miR-148
targeting of PCa drivers discovered in PCa CLIP data revealed that
six of the nine miR-148a PCa driver targets were decreased on average
between the LNCaP and HeLa datasets and eight of the nine PCa
driver targets were decreased specifically in the LNCaP dataset,
demonstrating a preponderance of mRNA loss in miR-148a predicted
targets (Table 1). In the Taylor PCa dataset [5], miR-148a negatively
correlated with seven of nine driver targets (Table 1). Of the two
driver targets miR-148a positively correlated with, one was AR, which
has been shown to induce miR-148a expression [17,19]. In this context,
our data suggest that miR-148a and AR together may mediate a feedback
loop on AR signaling. Taken together, the miR-148ab overexpression
microarray and anticorrelation analysis results indicated that miR-148a
has a predominantly inverse expression relationshipwith its CLIP-defined
driver targets, indicative of miR-148a regulation over these genes.
On average, across both the overexpression array and the PCa
anticorrelation analysis, miR-148a had the strongest negative
association with the oncogene CENPF and the tumor-suppressor
CDKN1B (Table 1). Interestingly, CDKN1B loss is an important
initiator of PCa [61], and CDKN1B is commonly mutated or deleted
early in PCa progression [5,6]. In contrast, CENPF is a master
regulator of metastasis in PCa [8,9]. As such, we hypothesized that
CDKN1B targeting by miR-148a drives PCa initiation and
miR-148a targeting of the metastatic driver CENPF during PCa
progression inhibits metastasis. This metastatic inhibition is lost when
miR-148a is silenced during later stages of the disease. To test this
hypothesis, we next focused on validating the putative interaction of
miR-148a with CDKN1B and CENPF using luciferase constructs,
with LNCaP as a model of early PCa and PC3 as a model of late PCa.
Transfection of miR-148a mimic into 293T cells was sufficient
to specifically suppress CDKN1B 3’UTR-luciferase reporter activityby
55.7%, andmiR-148a transfection into LNCaP cells was sufficient to suppress
CDKN1B protein levels demonstrating the specificity of the miR-148-
a:CDKN1B-3’UTR interaction (Figure 4E). miR-148a mimic did not
change luciferase expression relative to a control mimic in the same
CDKN1B 3’UTR construct with the miR-148a seed ablated
(Figure 4E). Silencing of CDKN1B by miR-148a is consistent with
the increase in proliferation (Figure 4C) through increased S-phase
transition (Supplementary Figure 2C) that we observed after miR-148a
transfection into LNCaP cells.
In human tumors, CENPF mRNA expression was modestly (14%)
increased in primary tumors but greatly increased in nodal and distant
metastases (75% increase in nodal metastases and 127% increase in
distant metastases; Figure 4F). CENPF mRNA expression was also
associated with poor BCR-free survival in primary tumors, indicating
that CENPF expression in the primary tumor predicts the
development of terminal disease (Figure 4G).
Despite data indicating that CENPF apparently supports PCa
metastasis [8,9], the in vitro function of CENPF in PC3 has largely
not been described. First, we investigated the miR-148a-CENPF
interaction. Similar to CDKN1B, miR-148a transfection into 293T
cells suppressed CENPF-3’UTR luciferase reporter activity by
28.7%, and miR-148a transfection into PC3 cells suppressed
CENPF protein expression demonstrating specific 3’UTR targeting
(Figure 4H). There was no difference between miR-148a and control
Figure 4.miR-148a is a homeostatic regulator of PCa throughCDKN1B andCENPF targeting. (A) In human tumors,miR-148a expression first
increased in primary tumors and then was sequentially silenced in nodal and distant metastases. (B) NativemiR-148a target sites occupied a
larger percentage of total target sites in LNCaP and LAPC4 cell lines than in the more anaplastic PC3 and DU145 cell lines. The number of
detectablemiR-148a family binding siteswas three timeshigher relative to the total binding sites inmiR-148a-transfectedPC3 cells. Error bars
are standard error of themean. (C) miR-148a increased proliferation in the LNCaP cell line by increasing the S-phase transition. (D) In the PC3
cell line, miR-148a greatly reduced cellular invasion through Matrigel. (E) 3’UTR-luciferase assays in 293T cells suggested that specific
targeting of miR-148a occurs on the 3’UTR of CDKN1B, and transfection of miR-148a mimic into LNCaP cells was sufficient to reduce
CDKN1B protein expression. (F) CENPF mRNA expression in human tumors was greatly increased in metastatic disease but only
slightly increased in primary tumors. (G) Primary human tumors in the upper quartile of CENPF expression predicted poor BCR-free
survival, indicating that CENPF may drive deadly high-grade disease. (H) Transfection of miR-148a into 293T cells specifically silenced a
CENPF-3’UTR luciferase construct, demonstrating the ability of miR-148a to reduce CENPF expression through interaction with its
3’UTR. Transfection of PC3 cells with miR-148a reduced native CENPF protein expression, whichmay account for the effect ofmiR-148a
on PC3 cellular migration and invasiveness. (I) siRNA-mediated specific knockdown of CENPF protein using siRNA cellular (J) migration and
(K) invasion is shown. *Pb .05, **Pb .005, ***Pb .0005 (t test). Error bars are standard error of the mean.
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miR-148a seed ablated (Figure 4H). Next, we determined whether
CENPF silencing could account for the known ability of miR-148a to
greatly reduce PC3 cellular migration and invasion. We found that
siRNAs directed against CENPF robustly silenced its protein
expression (Figure 4I), which corresponded with reduced cellular
migration (Figure 4J) and invasion (Figure 4K). Taken together, thesefindings suggest that CENPF is most active in driving PCa cell line
motility and EMT, and suppression of CENPF mirrored the effect of
miR-148a in PC3 cells.
In sum, our findings suggest a model of tumor progression
whereby miR-148a targeting may contribute to PCa initiation and
growth by targeting CDKN1B but inhibit metastasis by targeting
CENPF.
Table 1. Analysis of PCa Driver Genes Targeted by miR-148a in LNCaP and HeLa miR-148ab Overexpression Arrays
Driver
Target
Gene
Type Fold Change Pearson
Correlate
in Taylor
[5] data
Fold
Change +
Correlate
Average
HeLa-miR-148b [36] LNCaP-miR-148a [17] Array Average
CENPF Oncogene −0.988 −0.468 −0.728 −0.449 −0.588
CDKN1B Tumor suppressor −0.450 −0.242 −0.346 −0.114 −0.230
APC Tumor suppressor −0.187 −0.253 −0.220 −0.181 −0.200
MLL Oncogene – −0.036 −0.036 −0.233 −0.135
MYC Oncogene 0.068 −0.188 −0.060 −0.139 −0.100
FOXA1 Oncogene 0.271 −0.028 0.121 −0.163 −0.021
PTEN Tumor suppressor −0.300 0.383 0.042 −0.070 −0.014
PIK3CA Oncogene −0.266 −0.506 −0.386 0.377 −0.005
AR Oncogene 0.364 −0.265 0.050 0.334 0.192
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The significant enrichment of PCa driver targeting by miRNAs in
our CLIP data led us to hypothesize that global tissue-specific miRNA
targeting involves a homeostatic response to dominant driver
pathways. To test this hypothesis, we performed pathway analysis
on the panel of PCa cell lines to determine whether miRNA target
sites were enriched for dominant signaling pathways at different stages
of tumor progression. To examine stage-specific alterations, we
performed GSEA analysis of read depth differences at individual
target sites. Following gene ontology analysis, we mapped miRNAs
responsible for binding core pathway genes and thus identified the
miRNAs that, by targeting multiple core-enriched genes in a given
pathway, may be most responsible for regulation of that pathway.
First, we modeled miRNA targeting in CRPC in the 22Rv1 cell
line, which expresses the constitutively active ligand-independent AR
splice isoform AR-V7 (Supplementary Figure 2D and Supplementary
File 5 contain data describing significant changes in individual target
sites). Expression of AR-V7 has previously been shown to allow
persistent AR activity following castration [71] and drive a novel
AR-mediated gene program that differs from native AR [72]. GSEA
pathway analysis of miRNA 3’UTR targeting in 22Rv1 cells relative
to LNCaP and LAPC4 cells showed that the E2F response was the
strongest (most enriched), followed by the G2/M DNA damage
checkpoint and MYC-V1/2 targets (Figure 5A, Table 2). Interest-
ingly, the E2F and MYC pathways are associated with progression to
CRPC [10,11]. The fact that E2F signaling was the most heavily
enriched miRNA targeting pathway in AR-V7–expressing 22Rv1
cells relative to LNCaP and LAPC4 cells suggests a model in which
the miRNA pool reacts in a homeostatic fashion to equilibrate
dominant signaling pathways active in CRPC.
To determine which miRNAs are active in regulating the dominant
E2F signaling pathway, we tallied how many core-enriched genes
(genes defined as enriched in each pathway by GSEA) each miRNA is
capable of targeting to best determine which individual miRNA
families may have a strong influence over the entire signaling
pathway. We found that miR-145, miR-590, and miR-129 had the
most E2F core-enriched targets out of 126 miRNA families predicted
to target at least one core-enriched gene in the CLIP data (Figure 5, B
and C). Together, these three miRNAs are capable of targeting
69.7% of 66 E2F core-enriched genes with some overlap in their
targetomes. miR-145 has been previously demonstrated to be RB1
responsive and regulate E2F signaling [73].
We next analyzed differences between the AR-positive LNCaP,
LAPC4, and 22Rv1 cell lines and the AR-negative PC3 and DU145
cell lines. The AR-negative PCa cell lines had 27 significantlyupregulated (false discovery rate b 0.25) GSEA gene sets relative to
the AR-positive cell lines. EMT was the most significantly enriched
concept, followed by glycolysis, IFN-γ response, and hypoxia
(Figure 5D, Table 2).
Because EMT is a seminal process contributing to the ability of
tumors to undergo metastasis, we sought to determine which
miRNAs contributed to targeting EMT in the AR-negative PCa
cell lines. We found that the miR-138, miR-185, and miR-326
miRNA families were most strongly associated with the EMT
signature, targeting 73.1% of 26 EMT core-enriched targets
(Figure 5, E and F describes all EMT core targeting by these
miRNA families). miR-138 is a known suppressor of EMT [74].
Notably, miR-205, a well-described regulator of EMT and tumor
suppressor of PCa, was also high on the list (Figure 5E) [16].
Finally, we analyzed potential differences in miRNA targeting
between PCa cell lines and other tumorigenic cell lines in our CLIP
atlas. Genes active in oxidative phosphorylation were the most
significantly enriched (false discovery rate b 0.25) gene set in PCa cell
lines relative to all other cell lines (Figure 5G, Table 2). miRNA
targeting of genes related to oxidative phosphorylation in PCa cell lines
is of particular interest because of the unique metabolic reprogramming
of PCa. In contrast with many other cancers, PCa lipid synthesis and
anaplerosis support an oxidative metabolic program [26,75,76].
We investigated which miRNA families were actively targeting
oxidative phosphorylation by isolating miRNA families targeting the
29 significantly altered genes contributing to the core enrichment of
the oxidative phosphorylation pathways. In total, 126 separate
conserved miRNA families contained at least one predicted binding
site in the core genes. Of these 126 miRNA families, 99 were
predicted to target ≥2 of the core enriched genes, but only 8 miRNA
families were predicted to target ≥5 core genes (Figure 5H). Among
these 8 miRNA families, the miR-203 family targeted 8 of 29 enriched
genes (27.6%), and the miR-103 and miR-338 families each targeted 6
of 29 enriched genes (20.7%). Together, these 3 miRNA families
targeted 14 of 29 unique target genes (48.2%) with 6 overlapping
targets (Figure 5I), suggesting that these miRNAs may exert substantial
control over oxidative phosphorylation in PCa. All three of these
miRNA families are known regulators of energy metabolism;
knockdown of miR-203 blocks oxidative phosphorylation [77],
miR-103 is a critical regulator of insulin signaling [78], and miR-338
directly suppresses oxidative phosphorylation in neurons [79].
Androgen Blockade Suppresses miRNA Targeting
To further investigate the finding that miRNA targeting
produces a homeostatic response to flux in cellular pathways, we
Figure 5. MicroRNA targets are enriched in AR-negative PCa cell line genes related to the EMT pathway, and PCa cells, compared with
cells from other tumors, show enrichment of miRNAs targeting genes involved in oxidative phosphorylation. (A) Gene enrichment graph
and heat map showing that CRPC had greatly enriched miRNA targeting of the E2F pathway compared with castrate-sensitive PCa. (B–C)
E2F pathway targeting was driven by the miR-145, miR-590, and miR-129 miRNA families, suggesting that these miRNAs may regulate
unique pathways involved in castration resistance. (D) Gene enrichment graph and heat map showing that genes relating to EMT had the
most significantly different miRNA target pathways between AR-positive and AR-negative cell lines, reflecting increased metastatic
potential in AR-negative cell lines as well as the tendency of miRNAs to reactively target uniquely activated gene pathways. (E–F) The
miR-185, miR-138, and miR-326 families disproportionately targeted genes involved in EMT in PCa, suggesting that these miRNAs may
contribute to metastasis in PCa. miR-205, a known metastatic regulator of PCa, also selectively targeted EMT-related genes. (G) Gene
enrichment graph and heat map of genes involved in oxidative phosphorylation that were enriched in PCa cell lines compared with other
cancer cell lines. Enrichment of genes involved in oxidative phosphorylation in PCa cell lines indicates resistive activation of miRNA in
response to transcriptional upregulation of unique pathways. (H–I) The miR-203, miR-338, and miR-103/107 families were most
responsible for targeting of core-enriched genes related to oxidative phosphorylation in PCa.
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antagonist enzalutamide. The Venn diagram in Figure 6A illustrates
the overlap among unique mRNA targets in untreated LNCaP cells
compared with LNCaP cells treated with enzalutamide. A total of 2174
3’UTRs with at least 1 cluster were discovered. Of these, 1531 3’UTR
clusters were exclusive to untreated LNCaP cells, 288 3’UTR clusters
were exclusive to cells treated with enzalutamide (LNCaP-MDV3100),
and 355 3’UTR clusters appeared in both (Figure 6A, Supplementary
File 5). These data demonstrate globally decreased targeting of
individual mRNAs in the enzalutamide-treated samples, corroboratedby the fact that treatment with enzalutamide globally reduced miRNA
reads on the 3’UTR by ~25% (Supplementary Figure 2E).
Global loss of targeting in the treated cells was reflected in miRNA
driver target analysis as well. In total, cells treated with enzalutamide
had 70% fewer total mRNA targets and 60% fewer total driver target
interactions than untreated LNCaP cells (Figure 6B shows all drivers
with at least one miRNA-target interaction discovered in the
untreated LNCaP and treated LNCaP datasets).
Both KEGG and GSEA analyses showed that the TP53 pathway
was significantly enriched in untreated LNCaP cells compared with
Table 2. GSEA Analysis of miRNA Targeting in PCa
Comparison Gene Sets NES NOM P val FDR Q val
Castrate-resistant vs castrate–sensitive cells HALLMARK_E2F_TARGETS 1.85 .00 .02
HALLMARK_G2M_CHECKPOINT 1.81 .00 .02
HALLMARK_MYC_TARGETS_V2 1.38 .05 .29
HALLMARK_MYC_TARGETS_V1 1.35 .11 .26
AR-negative vs AR-positive cells HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 2.18 .00 .01
HALLMARK_GLYCOLYSIS 1.94 .00 .01
HALLMARK_INTERFERON_GAMMA_RESPONSE 1.91 .00 .01
HALLMARK_HYPOXIA 1.87 .00 .01
HALLMARK_INTERFERON_ALPHA_RESPONSE 1.83 .03 .01
HALLMARK_INFLAMMATORY_RESPONSE 1.72 .00 .03
HALLMARK_IL6_JAK_STAT3_SIGNALING 1.70 .00 .03
HALLMARK_IL2_STAT5_SIGNALING 1.68 .00 .03
HALLMARK_APICAL_JUNCTION 1.65 .00 .04
HALLMARK_ALLOGRAFT_REJECTION 1.63 .00 .04
HALLMARK_UV_RESPONSE_DN 1.60 .03 .04
HALLMARK_COMPLEMENT 1.60 .02 .04
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.56 .00 .05
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 1.54 .01 .06
HALLMARK_APOPTOSIS 1.51 .04 .07
HALLMARK_COAGULATION 1.51 .08 .07
HALLMARK_ESTROGEN_RESPONSE_LATE 1.47 .01 .08
HALLMARK_TNFA_SIGNALING_VIA_NFKB 1.45 .00 .09
HALLMARK_MITOTIC_SPINDLE 1.44 .04 .09
HALLMARK_WNT_BETA_CATENIN_SIGNALING 1.37 .08 .13
HALLMARK_MYOGENESIS 1.36 .11 .14
HALLMARK_PROTEIN_SECRETION 1.32 .07 .18
HALLMARK_MTORC1_SIGNALING 1.31 .14 .17
HALLMARK_PI3K_AKT_MTOR_SIGNALING 1.29 .08 .19
HALLMARK_TGF_BETA_SIGNALING 1.25 .20 .22
HALLMARK_MYC_TARGETS_V2 1.24 .16 .22
HALLMARK_XENOBIOTIC_METABOLISM 1.22 .16 .24
PCa vs other cancer cells HALLMARK_OXIDATIVE_PHOSPHORYLATION 1.66 .01 .21
LNCaP vs LNCaP-MDV3100 HALLMARK_P53_PATHWAY 1.81 .01 .02
HALLMARK_TNFA_SIGNALING_VIA_NFKB 1.49 .06 .10
HALLMARK_MTORC1_SIGNALING 1.34 .12 .15
HALLMARK_MYC_TARGETS_V1 1.22 .21 .21
NES indicates normalized enrichment score; FDR, false discovery rate. The P value represents a normal distribution.
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reflects known cooperative functionality between TP53 and AR
signaling [80,81] and the known activation of TP53 by AR-induced
miRNAs [20]. Interestingly, three of five KEGG pathways gained
after treatment with enzalutamide were related to PI3K signaling
(Supplementary File 6). This finding could reflect the fact that in
PTEN-deficient PCa cells such as LNCaP cells, loss of AR signaling
leads to PI3K activation mediated by PI3KCD [82]. As such, it is
apparent that the miRNA interactome is not simply lost upon
deprivation of host transcripts but shifts to host transcripts that are
activated after AR loss.
Activated Gene Pathways are Associated with Human PCa
To substantiate our findings in human PCa data, we analyzed
correlations of the core-enriched pathway driver genes targeted by
miRNAs in our analysis with clinical outcomes in human PCa. To do
this, we assigned each sample in the Taylor PCa dataset [5] an activity
score for the core-enriched genes based on the mRNA expression of
each core component. We first performed quartile analysis of the top
two significant gene sets for each GSEA comparison (EMT and
glycolysis in AR-positive cells compared with AR-negative cells, E2F
and G2M in castrate-sensitive PCa compared with CRPC, and
oxidative phosphorylation in PCa compared with other cancers)
identified in our analysis to determine clinical correlations with
BCR-free survival.We found that the upper quartile of core-enriched genes in the E2F
pathway and the upper half of core-enriched genes in the G2M
pathway were associated with poor BCR-free survival (Figure 6C).
The EMT, glycolysis, and oxidative phosphorylation core enrich-
ments were not associated with BCR-free survival, likely because the
EMT and glycolysis pathways reflect AR-negative disease, which is
not present in the Taylor data, and the oxidative phosphorylation
pathway is constitutively active across PCa specimens.
Because the EMT and G2M pathways enriched in CRPC were
associated with BCR-free survival, we further analyzed clinical end
points associated with the enrichment of these pathways. We found
that E2F and G2M core-enriched genes were also associated with
poor combined Gleason score at biopsy (Figure 6D). The activity
scores of the E2F and G2M pathway components were significantly
correlated with each other (Supplementary Figure 2F), which likely
reflect components of the E2F pathway driving cellular movement
through the G2M checkpoint.
These results are consistent with the known role of the E2F
pathway in driving castration resistance and BCR. These results
suggest that primary tumors express core-enriched E2F pathway
components and are more likely to undergo rapid BCR than tumors
with reduced expression of core-enriched E2F pathway components.
Finally, these results demonstrate that, in models of CRPC, the
miRNA pool responds to mRNAs that are predictive of poor outcome
and high-grade initial disease in human tumors.
Figure 6.MicroRNA targeting in the 3’UTR is globally reduced after treatment with enzalutamide. (A) Inhibition of the AR by enzalutamide
(LNCaP-MDV3100 cells) globally decreased the total number of discovered miRNA cluster sites while simultaneously activating a novel,
specific set of miRNA targets. (B) 3’UTR read enrichment in the 3’UTR was reduced by ~25% upon treatment with enzalutamide,
reflecting either global reduction in miRNA binding ability or global reduction in 3’UTR expression. (C) E2F and G2M pathway
core-enriched genes were associated with poor BCR-free survival. (D) E2F and G2M pathway component expression was associated with
a high-grade Gleason score upon prostate biopsy. *Pb .05, **Pb .005 (t test).
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In the current study, we used AGO-CLIP-Seq technology to define
miRNA target interactions in common models of human PCa
progression. PCa is a leading cause of cancer-related death in men.
Furthermore, miRNA deregulation in cancer is known to drive PCa
progression. As such, in-depth understanding of miRNA targeting at
different stages of PCa is of considerable value to the research
community.
Initial analysis of miRNA targeting of known drivers of PCa
demonstrated enrichment in driver targeting that is indicative of
continued miRNA-mediated modulation of oncogenic pathways,
even in models of advanced PCa. The AR 3’UTR underwent the
most miRNA-mediated regulation of any driver gene. AR is also a
well-described positive regulator of RNA transcription, and the
apparent regulation of AR by miRNAs is indicative of a negative
feedback loop initiated by many miRNA families. The heavy
targeting of AR has broad implications for understanding the role
of miRNA in PCa because of the important role AR plays in
tumorigenesis and therapeutic resistance.We found that miR-148a and miR-203 may play critical roles in
the development and progression of PCa. We found that miR-148a
targeted the most PCa drivers and was, on average, the most expressed
miRNA in PCa cell lines. Previous research into the role of miR-148a
in PCa has proven controversial, with divergent phenotype results
depending on the cell line. We further defined the miR-148a
targetome by examining its extensive targeting of drivers of PCa and
analyzing its expression in human tumor progression. Our results
elucidate the role of miR-148a; we found that it undergoes
stage-specific regulation in PCa, targeting both known PCa
oncogenes and known PCa tumor suppressors. Although we focused
specifically on the interaction of miR-148a with CDKN1B and
CENPF, miR-148a also contained N300 targets in our PCa CLIP
datasets, and its full function is likely driven by the integration of
these interactions.
miR-203 was also among the miRNAs with the most driver targets,
and it is well described as a tumor suppressor in PCa [15,16,18]. Most
of the PCa drivers (seven of eight) that were targeted by miR-203
were oncogenes. Furthermore, miR-203 was also a primary regulator
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and the core-enriched genes targeted by miR-203 were part of a
signature that was associated with poor BCR-free survival and
high-grade initial disease (Figure 6C). Taken together, these findings
indicate that miR-203 regulates PCa at multiple levels by targeting
primary PCa oncogenes, disrupting pathways that contribute to
castration resistance, and possibly interfering with oxidative phos-
phorylation, upon which PCa is uniquely dependent. These findings
further clarify the mechanisms behind the known tumor-suppressive
activity of miR-203 [16,18].
After observing strong targeting of PCa drivers across tumor cells lines,
we hypothesized that the miRNA pool may regulate dominant driver
pathways. Primary PCa is primarily driven by increased fatty acid
oxidation and electron transport chain activity [26]. However, in
advanced and distantmetastatic disease, glycolytic pathways are activated,
potentially as a result of a hypoxic response [83]. Activation of these
pathways is associated with aggressive tumors and poor prognosis [83].
Furthermore, the E2F andMyc pathways are specifically activated during
castration resistance and directly contribute to advanced, therapy-resis-
tant PCa. This stage-specific pathway alteration was directly mirrored in
our PCa CLIP data in various models of tumor progression. The
rediscovery of pathways known to be important drivers in PCa
progression via an orthogonal approach using AGO-CLIP-Seq validates
the use of a CLIP-based approach to identify dominant driver pathways
and possibly nominate novel pathways in an unbiased manner, such as
the G2M checkpoint barrier that we identified in the analysis of CRPC.
The discovery of E2F, Myc, EMT, and glycolytic pathway involvement
in PCa in our CLIP analysis demonstrates how the miRNA targetome
can perfectly adapt to the vast differences in molecular physiology that
occur during staged PCa progression.
As such, a primary finding of this research is that the miRNA pool
performs remarkably specific homeostatic tracking of active mRNA
pathways both globally and on the level of individual miRNAs. These
findings demonstrate that the miRNA targetome adapts to
accommodate and repress newly active molecular pathways during
clinical progression. Such adaptation by the miRNA pool in response
to gene changes is documented [84,85], but our results define the
consequence of such adaptation during tumorigenesis. This observa-
tion is important because it suggests that even in advanced tumors, in
which expression of oncogenic miRNAs is greatly increased, the
miRNA pool is still binding and suppressing tumor-promoting
programs. These findings are especially enlightening because recently
published studies have reported that components of the effector RISC
complex themselves undergo regulation [86,62], thereby suggesting
that global miRNA binding activity is modifiable. In this
circumstance, latent tumor-suppressive miRNA activity could be
reactivated to increase suppression of key tumor programs, which
could prove to be a viable future therapeutic mechanism.
Conclusions
In the current study, we implemented AGO-PAR-CLIP to analyze
the miRNA interactome in multiple PCa cell lines. We used our
novel, prostate-specific datasets as well as our larger CLIP atlas to
characterize multiple aspects of miRNA binding in PCa. We then
analyzed clinical associations between the identified pathways and
human PCa. These findings offer a unique insight into how miRNAs
function in a tissue-specific manner. Finally, we used our CLIP data
to define potential tumor-driving interactions of miR-148a, and we
found that CDKN1B targeting by miR-148a could promote PCainitiation but CENPF targeting by miR-148a could inhibit PCa
invasion.
By identifying miRNA families that have enriched targeting of
tumor-driving pathways as defined in the CLIP data, we were able to
directly identify which miRNAs are responsible for the observed
pathway enrichments. This type of progressive analysis of molecular
pathways active at different stages of PCa is critical to the future of
PCa research because new, highly aggressive tumors occur more often
after long-term treatment with next-generation antiandrogens. In
PCa, the primary unique miRNA targeting pathways active in
advanced disease relative to low-grade disease and in PCa tissue
relative to other tissues, such as the E2F pathway in CRPC, EMT and
glycolysis pathways in AR-negative PCa, and oxidative phosphory-
lation in PCa cell lines (relative to other cancer cell lines), are precisely
the type of tumor-driving programs that would be ideal to suppress
therapeutically.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.04.008.
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